agilon health (AGL) Stock Overview
Provides healthcare services for seniors through primary care physicians in the communities of the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
AGL Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
agilon health, inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$129.84 |
| 52 Week High | US$133.04 |
| 52 Week Low | US$7.48 |
| Beta | 3 |
| 1 Month Change | 14.09% |
| 3 Month Change | 358.80% |
| 1 Year Change | 144.98% |
| 3 Year Change | -71.68% |
| 5 Year Change | -85.92% |
| Change since IPO | -83.25% |
Recent News & Updates
Narrative Update • Jul 07
AGL: Raised Outlook And Leadership Shift Will Support Future Upside
Analysts have lifted their price target for agilon health from $95.00 to $120.00, citing updated assumptions around revenue growth, profit margins, fair value and future P/E that support a higher assessed valuation. What’s in the News for agilon health agilon health reported first quarter 2026 net income of US$49 million compared with US$12 million a year earlier, with results attributed to medical margin performance, contract economics and operating discipline, according to recent earnings coverage.Seeking Alpha • Jun 24
agilon health: Q1 Inflection And A New CEO Set Up A Multi-Year Rerating
Summary agilon health is rated Buy with a $177 price target, reflecting a robust Q1 beat and a positive inflection in financials. Q1 2026 delivered $1.42B revenue (+$40M vs. consensus), $54M adjusted EBITDA (+162% YoY), and raised full-year guidance across all key metrics. Margin expansion is driven by a new data pipeline, scaled clinical programs, disciplined payer contracting, and AI-driven risk scoring now fully operational. Read the full article on Seeking Alpha
Narrative Update • Jun 23
AGL: Reverse Split And Rich P/E Will Constrain Future Share Returns
The analyst price target for agilon health has moved from $6.25 to $22.00. Analysts tie this change to updated assumptions for revenue trajectory, profit margins, and future P/E expectations under a slightly higher discount rate.Recent updates
Narrative Update • Jul 07
AGL: Raised Outlook And Leadership Shift Will Support Future Upside
Analysts have lifted their price target for agilon health from $95.00 to $120.00, citing updated assumptions around revenue growth, profit margins, fair value and future P/E that support a higher assessed valuation. What’s in the News for agilon health agilon health reported first quarter 2026 net income of US$49 million compared with US$12 million a year earlier, with results attributed to medical margin performance, contract economics and operating discipline, according to recent earnings coverage.Seeking Alpha • Jun 24
agilon health: Q1 Inflection And A New CEO Set Up A Multi-Year Rerating
Summary agilon health is rated Buy with a $177 price target, reflecting a robust Q1 beat and a positive inflection in financials. Q1 2026 delivered $1.42B revenue (+$40M vs. consensus), $54M adjusted EBITDA (+162% YoY), and raised full-year guidance across all key metrics. Margin expansion is driven by a new data pipeline, scaled clinical programs, disciplined payer contracting, and AI-driven risk scoring now fully operational. Read the full article on Seeking AlphaNarrative Update • Jun 23
AGL: Reverse Split And Rich P/E Will Constrain Future Share Returns
The analyst price target for agilon health has moved from $6.25 to $22.00. Analysts tie this change to updated assumptions for revenue trajectory, profit margins, and future P/E expectations under a slightly higher discount rate.
Narrative Update • Jun 05
AGL: Reverse Split And Q1 Euphoria Will Expose 2026 Downside Risk
Analysts have raised their fair value estimate for agilon health from $19.67 to about $60.36, citing updated views on revenue growth, profit margins, discount rates, and future P/E assumptions. What's in the News Agilon health reported first quarter 2026 results with earnings and revenue above expectations, net income of $49 million compared with $12 million a year earlier, supported by higher medical margins, improved contract terms, and stronger risk scores.Narrative Update • May 22
AGL: Reverse Stock Split And Upgraded Outlook Will Support Future Upside
Analysts have increased their price target for agilon health to $95.00, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E as the key factors behind the revision. What's in the News agilon health issued earnings guidance for the first quarter ending March 31, 2026, with expected total revenues between US$1,350 million and US$1,390 million, and for the 2026 fiscal year with expected total revenues between US$5,410 million and US$5,580 million (Company guidance).Narrative Update • May 03
AGL: Reverse Stock Split Will Sustain Pressure On Future Share Returns
Analysts have modestly lowered their price target on agilon health to $6.25, reflecting updated expectations for slightly softer revenue growth and a marginally higher profit margin, while keeping core valuation and discount rate assumptions unchanged. What's in the News Agilon health plans to implement a 1 for 25 reverse stock split of its common stock, expected to become effective on March 30, 2026.Narrative Update • Apr 18
AGL: Reverse Stock Split Will Expose Downside Risk To 2026 Outlook
Analysts have raised their price target on agilon health to $19.67 from $0.94, reflecting updated assumptions related to fair value, revenue growth, profit margins and future P/E expectations. What's in the News A reverse stock split of agilon health common stock at a 1-for-25 ratio was approved by the board on March 17, 2026.Narrative Update • Apr 03
AGL: Reverse Stock Split And Lawsuit Risk Will Pressure Future Shares
Analysts have reset their view on agilon health, with the implied fair value estimate moving sharply from $0.25 to $6.25. This reflects updated assumptions around revenue growth, profit margins and future P/E expectations.Narrative Update • Mar 20
AGL: Reverse Split And 2026 Revenue Outlook Will Support Bullish Repricing
Analysts have raised their price target on agilon health by $X.XX to $Y.YY, citing updated views on profit margin, revenue growth and future P/E assumptions that modestly adjust their long term expectations for the business. What's in the News agilon health plans a 1-for-25 reverse stock split of its common stock, expected to become effective on March 30, 2026, with trading on a split-adjusted basis on the NYSE starting March 31, 2026 under the ticker AGL, intended to keep the share price above $1.00 and comply with NYSE minimum bid requirements (Key Developments).Narrative Update • Mar 06
AGL: Reverse Split And Guidance Reset Will Support Bullish Repricing
Analysts have trimmed their price target on agilon health to reflect a modest reset in fair value to $0.94 from $0.99, citing updated views on revenue growth, profit margins, and future P/E assumptions. What's in the News agilon health issued earnings guidance for the first quarter ending March 31, 2026, with expected total revenues between US$1,350m and US$1,390m, and for the full year 2026 with expected total revenues between US$5,410m and US$5,580m (Corporate guidance).Narrative Update • Feb 20
AGL: Reverse Stock Split Proposal Will Drive Cautious Outlook For Shares
Analysts have modestly raised their price target on agilon health, citing updates to assumptions around revenue growth, profit margins, and future P/E levels, which together point to a slightly higher implied valuation in dollar terms for the shares. What's in the News agilon health scheduled a special meeting of stockholders for March 17, 2026 to vote on an amendment to its certificate of incorporation that would allow a reverse stock split of the common stock at a ratio between one for five and one for twenty five, with the exact ratio to be set by the board of directors and no change to the authorized share count (Key Developments).Narrative Update • Feb 06
AGL: Index Removal And Refined Assumptions Will Support Bullish Outlook
Analysts have modestly lifted their price target on agilon health, citing small adjustments to fair value estimates, discount rate assumptions, and future P/E expectations that together point to a slightly higher implied equity value for shareholders. What's in the News agilon health, inc.Narrative Update • Jan 22
AGL: Planned Reverse Stock Split Will Support Future Listing Compliance
Narrative Update Analysts trimmed their price target on agilon health by a small amount, to a level they see as consistent with updated views on fair value, discount rates, revenue growth, profit margins and a higher assumed future P/E. What's in the News agilon health was notified that its stock is not in compliance with NYSE listing standards because the average closing price was under $1.00 per share over a 30 trading day period ended November 4, 2025, and the company plans to pursue a reverse stock split, subject to stockholder approval at the 2026 annual meeting (Key Developments).Narrative Update • Jan 08
AGL: Listing Compliance Risks Will Drive Cautious Outlook For Shares
Analysts have reduced their price targets on agilon health, citing updated views that now reflect a lower fair value estimate, a higher discount rate, more cautious revenue growth assumptions, and a reduced future P/E, partially offset by a slightly higher projected profit margin. What's in the News agilon health, inc.Narrative Update • Dec 24
AGL: Higher Profit Margins And Reverse Split Will Support Future Upside
Analysts have raised their price target on agilon health to reflect a substantially higher profit margin outlook and sharply lower future earnings multiple, despite moderating assumptions for revenue growth and a slightly higher discount rate. What's in the News agilon health, inc.Narrative Update • Dec 10
AGL: Fiscal 2025 Guidance And Reverse Split Will Support Bullish Outlook
Analysts have trimmed their price target on agilon health by roughly 4 percent to reflect slightly softer expectations for revenue growth, profitability, and future valuation multiples while maintaining a largely similar risk profile. What's in the News New York Stock Exchange notified agilon health that its shares no longer meet the minimum 1 dollar average closing price requirement over a 30 day trading period, which triggered a cure period while the stock remains listed and traded on the NYSE (Key Developments).Narrative Update • Nov 26
AGL: Fiscal 2025 Revenue Guidance Will Sustain Positive Momentum For Shares
Analysts have lowered their price target for agilon health to $1.01 from $1.23. This reflects a more cautious outlook based on adjustments to expected revenue growth and a modestly higher discount rate, despite slight improvement in profit margin estimates.Analysis Article • Nov 07
Analysts Have Been Trimming Their agilon health, inc. (NYSE:AGL) Price Target After Its Latest Report
It's been a mediocre week for agilon health, inc. ( NYSE:AGL ) shareholders, with the stock dropping 13% to US$0.70 in...Narrative Update • Nov 05
AGL: Fiscal 2025 Revenue Guidance Will Drive Renewed Confidence In Outlook
Analysts have modestly increased their price target for agilon health from $1.23 to $1.23 per share. This reflects steady expectations for the company's valuation despite minor adjustments in forecasts for growth and margins.Narrative Update • Oct 22
Analyst Price Target for agilon health Rises Amid Leadership Changes and Updated Profit Margin Forecasts
Analysts have raised their price target for agilon health to $1.23 from $1.22 per share. This change reflects slight improvements in profit margin expectations, despite moderately lower anticipated revenue growth.Narrative Update • Oct 08
Aging Demographics And Medicare Advantage Will Advance Value Based Care
Analysts have lowered their fair value estimate for agilon health from $1.55 to approximately $1.22. This change is due to more cautious expectations for revenue growth and profit margins in the updated models.Analysis Article • Oct 02
Health Check: How Prudently Does agilon health (NYSE:AGL) Use Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narrative Update • Aug 16
Aging Demographics And Medicare Advantage Will Advance Value Based Care
agilon health’s consensus price target has been revised downward, primarily reflecting declines in its future P/E ratio and slightly lower net profit margin, with fair value now set at $1.74. What's in the News The Board amended and restated the by-laws to refine officer roles and align with updates in Delaware law.Analysis Article • Aug 02
Positive Sentiment Still Eludes agilon health, inc. (NYSE:AGL) Following 29% Share Price Slump
To the annoyance of some shareholders, agilon health, inc. ( NYSE:AGL ) shares are down a considerable 29% in the last...Analysis Article • Jul 01
Is agilon health (NYSE:AGL) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • May 09
Investors Give agilon health, inc. (NYSE:AGL) Shares A 40% Hiding
agilon health, inc. ( NYSE:AGL ) shareholders won't be pleased to see that the share price has had a very rough month...
New Narrative • Mar 24
Medicare Shifts Will Limit Revenue And Spur Operational Gains
Reduction in Medicare Part D exposure aims to lower volatility but could lead to decreased revenue from this segment.Analysis Article • Mar 19
agilon health, inc.'s (NYSE:AGL) Shares Leap 26% Yet They're Still Not Telling The Full Story
agilon health, inc. ( NYSE:AGL ) shares have continued their recent momentum with a 26% gain in the last month alone...Analysis Article • Feb 28
agilon health, inc. (NYSE:AGL) Analysts Are Pretty Bullish On The Stock After Recent Results
agilon health, inc. ( NYSE:AGL ) shareholders are probably feeling a little disappointed, since its shares fell 7.5% to...Analysis Article • Jan 14
Further Upside For agilon health, inc. (NYSE:AGL) Shares Could Introduce Price Risks After 29% Bounce
agilon health, inc. ( NYSE:AGL ) shareholders are no doubt pleased to see that the share price has bounced 29% in the...Analysis Article • Nov 10
agilon health, inc. (NYSE:AGL) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny
To the annoyance of some shareholders, agilon health, inc. ( NYSE:AGL ) shares are down a considerable 43% in the last...Seeking Alpha • Nov 08
agilon health Plunges On A Poor Prognosis (Rating Downgrade)
Summary I initially rated agilon health, inc. as a “hold” due to its volatile financial results and uncertain future, but recent developments necessitate a downgrade to 'sell'. The company's stock plummeted 60.1% since my last article, driven by disappointing Q3 results and reduced guidance, despite revenue growth. Rising medical costs and expansion expenses have severely impacted profitability, with a significant increase in net loss and negative EBITDA. Although agilon health has substantial cash reserves, the drastic downward revision in guidance and ongoing cost uncertainties undermine investor confidence. Read the full article on Seeking AlphaAnalysis Article • Oct 15
Rock star Growth Puts agilon health (NYSE:AGL) In A Position To Use Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Aug 16
agilon health: Interesting Business Model, But Volatile And Uncertain
Summary agilon hagilon healthealth shares dropped significantly after disappointing financial results, down 11.9% in two days. The company's revenue surged 38.7% year over year, but its net loss nearly doubled, and guidance for 2024 is mixed. Concerns include declining cash reserves, potential for further dilution, and uncertainty regarding share valuation. Read the full article on Seeking AlphaAnalysis Article • Aug 16
Market Cool On agilon health, inc.'s (NYSE:AGL) Revenues Pushing Shares 34% Lower
agilon health, inc. ( NYSE:AGL ) shares have had a horrible month, losing 34% after a relatively good period...Analysis Article • Jul 15
Rock star Growth Puts agilon health (NYSE:AGL) In A Position To Use Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Shareholder Returns
| AGL | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 13.1% | -0.3% | -2.0% |
| 1Y | 145.0% | 39.3% | 17.4% |
Return vs Industry: AGL exceeded the US Healthcare industry which returned 39.3% over the past year.
Return vs Market: AGL exceeded the US Market which returned 17.4% over the past year.
Price Volatility
| AGL volatility | |
|---|---|
| AGL Average Weekly Movement | 36.0% |
| Healthcare Industry Average Movement | 7.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: AGL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AGL's weekly volatility has increased from 25% to 36% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 856 | Tim O’Rourke | www.agilonhealth.com |
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021.
agilon health, inc. Fundamentals Summary
| AGL fundamental statistics | |
|---|---|
| Market cap | US$2.17b |
| Earnings (TTM) | -US$373.54m |
| Revenue (TTM) | US$5.82b |
0.4x
P/S Ratio-5.8x
P/E RatioIs AGL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGL income statement (TTM) | |
|---|---|
| Revenue | US$5.82b |
| Cost of Revenue | US$5.97b |
| Gross Profit | -US$145.73m |
| Other Expenses | US$227.82m |
| Earnings | -US$373.54m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 05, 2026
| Earnings per share (EPS) | -22.39 |
| Gross Margin | -2.50% |
| Net Profit Margin | -6.42% |
| Debt/Equity Ratio | 16.5% |
How did AGL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/19 05:32 |
| End of Day Share Price | 2026/07/17 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
agilon health, inc. is covered by 25 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hua Ha | Baird |
| Andrew Mok | Barclays |
| William Sutherland | Benchmark Company |